These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 22323742

  • 1. Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: when tolvaptan becomes a life saving drug.
    Graziani G, Cucchiari D, Aroldi A, Angelini C, Gaetani P, Selmi C.
    J Neurol Neurosurg Psychiatry; 2012 May; 83(5):510-2. PubMed ID: 22323742
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants.
    Marx-Berger D, Milford DV, Bandhakavi M, Van't Hoff W, Kleta R, Dattani M, Bockenhauer D.
    Acta Paediatr; 2016 Jul; 105(7):e334-7. PubMed ID: 27028950
    [Abstract] [Full Text] [Related]

  • 4. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
    Tzoulis P, Waung JA, Bagkeris E, Carr H, Khoo B, Cohen M, Bouloux PM.
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
    [Abstract] [Full Text] [Related]

  • 5. Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
    Pose-Reino A, Runkle de la Vega I, de Jong-Laird A, Kabra M, Lindner U.
    Adv Ther; 2021 Feb; 38(2):1055-1067. PubMed ID: 33306187
    [Abstract] [Full Text] [Related]

  • 6. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
    Humayun MA, Cranston IC.
    BMC Endocr Disord; 2017 Nov 06; 17(1):69. PubMed ID: 29110656
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tolvaptan: any evidence of efficacy in SIADH?
    Prescrire Int; 2010 Oct 06; 19(109):197-200. PubMed ID: 21180368
    [Abstract] [Full Text] [Related]

  • 9. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ, Ahmad F, Blais JD, Chiodo J, Zhou W, Glaser LA, Czerwiec FS.
    Cancer Med; 2017 Apr 06; 6(4):723-729. PubMed ID: 28251822
    [Abstract] [Full Text] [Related]

  • 10. Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH).
    Harbeck B, Lindner U, Haas CS.
    Endocrine; 2016 Sep 06; 53(3):872-3. PubMed ID: 26961548
    [No Abstract] [Full Text] [Related]

  • 11. [The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].
    Rollino C, Balbiano R, Caramello P, Roccatello D.
    G Ital Nefrol; 2013 Sep 06; 30(6):. PubMed ID: 24402662
    [Abstract] [Full Text] [Related]

  • 12. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) due to bortezomib in a case of light chain multiple mieloma. Treatment with tolvaptan.
    Carreño A, Hernández B, Mayoralas Á, Calle C.
    Nefrologia; 2017 Sep 06; 37(5):558-559. PubMed ID: 28946972
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
    Bordi P, Tiseo M, Buti S, Regolisti G, Ardizzoni A.
    Tumori; 2015 Apr 28; 101(2):e51-3. PubMed ID: 25702667
    [Abstract] [Full Text] [Related]

  • 14. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
    De Las Peñas R, Ponce S, Henao F, Camps Herrero C, Carcereny E, Escobar Álvarez Y, Rodríguez CA, Virizuela JA, López López R.
    Support Care Cancer; 2016 Jan 28; 24(1):499-507. PubMed ID: 26431960
    [Abstract] [Full Text] [Related]

  • 15. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice.
    Rajendran R, Grossman AB, Kar P.
    Endocr J; 2012 Jan 28; 59(10):903-9. PubMed ID: 22785335
    [Abstract] [Full Text] [Related]

  • 16. [Lower doses of tolvaptan in hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion].
    Sánchez Sobrino P, Fernández Catalina P, Lorenzo Solar M, Rego Iraeta A.
    Med Clin (Barc); 2015 Aug 07; 145(3):138-9. PubMed ID: 25543222
    [No Abstract] [Full Text] [Related]

  • 17. Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm.
    Yamashita T, Yoshida M, Yamada H, Asano T, Aoki A, Ikoma A, Kusaka I, Kakei M, Ishikawa SE.
    Intern Med; 2014 Aug 07; 53(8):845-9. PubMed ID: 24739604
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, Liu ZM, Ma JH, Zhang ZW, Gu F.
    J Clin Pharmacol; 2014 Dec 07; 54(12):1362-7. PubMed ID: 24906029
    [Abstract] [Full Text] [Related]

  • 19. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V, Mladsi D, Ronquest N, Kamat S, Boklage S.
    Hosp Pract (1995); 2017 Aug 07; 45(3):111-117. PubMed ID: 28449624
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
    Dasta JF, Chiong JR, Christian R, Lin J.
    Hosp Pract (1995); 2012 Feb 07; 40(1):7-14. PubMed ID: 22406878
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.